眼科手术机器人企业迪视医疗完成数千万A2轮融资，老股东磐霖资本继续加码

Core Viewpoint - Recently, Hangzhou Disi Medical Biotechnology Co., Ltd. completed several million yuan in A2 round financing, led by Dacheng Caizhi, with existing shareholder Panlin Capital participating again. This funding will accelerate the market penetration of Disi Medical's ultra-microsurgery robots [1]. Group 1: Company Overview - Disi Medical focuses on the development of ultra-microsurgery robots, aiming to address unmet clinical needs in the field of microsurgery by overcoming the limitations of human hand operations [3]. - The company has launched a series of products, including ophthalmic surgical robots and microsurgery robots, and is actively pursuing a global strategy to benefit patients worldwide with its original ultra-microsurgery technology [7]. Group 2: Technological Advancements - Disi Medical's ultra-microsurgery technology allows for precise operations at the micron level, significantly reducing surgical damage and enabling the precise delivery of innovative drugs for retinal disease patients [3]. - The company has successfully completed the first robot-assisted lymphatic-venous anastomosis (LVA) reconstruction surgery in China, demonstrating superior stability and safety in addressing complex conditions like post-tumor lymphedema [5]. Group 3: Market Potential - The ultra-microsurgery robot segment is viewed as a blue ocean market within the surgical robotics field, with significant potential to meet the clinical demands of a large patient population, particularly in ophthalmology, where there are over 50 million patients with retinal diseases in China [3].